Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 13/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437554 | 0.94 | PTGS1 (0.46) | PTGS1KCNK3PDGFRBKDRMAPT | |
| SCHEMBL5440393 | 0.90 | KCNK3 (0.51) | PTGS1KCNK3PDGFRBKDRMAPT | |
| SCHEMBL5448822 | 0.90 | KCNK3 (0.46) | PTGS1KCNK3PDGFRBKDRMAPT | |
| SCHEMBL5438536 | 0.89 | MEN1 (0.48) | PTGS1KCNK3PDGFRBKDRMAPT | |
| SCHEMBL5438554 | 0.89 | BRAF (0.43) | PTGS1KCNK3MAPTBRAFLMNA | |
| SCHEMBL5447269 | 0.88 | KCNK3 (0.44) | PTGS1KCNK3PDGFRBKDRMAPT | |
| SCHEMBL5439090 | 0.87 | BRAF (0.44) | KCNK3MAPTBRAFMEN1HTT | |
| SCHEMBL5436375 | 0.87 | BRAF (0.50) | PTGS1KCNK3MAPTBRAFLMNA | |
| SCHEMBL5435141 | 0.87 | BRAF (0.46) | KCNK3MAPTBRAFLMNAMEN1 | |
| SCHEMBL5438545 | 0.87 | BRAF (0.53) | KCNK3MAPTBRAFLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219183-A1 | Dihydropyrazolo[1,5-A]pyrimidine and dihydroimidazo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH (US) | 2007-09-20 | — | — | US | claimed |
| US-20070219183-A1 | Dihydropyrazolo[1,5-A]pyrimidine and dihydroimidazo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219183-A1 | Dihydropyrazolo[1,5-A]pyrimidine and dihydroimidazo[1,5-A]pyrimidine derivatives and methods of use thereof | DPYD, DUT, TYMP | PTGS1 1168/4885KCNK3 3374/4885PDGFRB 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.